Allergy Immunotherapy Market by Treatment Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Tablets, and Drops), Allergy Type (Allergic rhinitis, Allergic asthma, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global allergy immunotherapy market size was valued at USD 1.6 billion in 2019 and is estimated to expand at a CAGR of 9% during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of allergic disorders.

Immunotherapy is a medication that helps people avoid allergic responses to things like grass pollen, home dust mites, and bee venom. Immunotherapy includes slowly increasing dosages of the substance, or allergen, to which the patient is allergic. The immune system becomes less sensitive to the allergen as the dose increases, most likely through triggering the development of a "blocking" antibody, which lessens allergy symptoms when the chemical is met again.

Immunotherapy can also help in rhinitis and asthma by reducing inflammation. The allergist and the patient identify allergy trigger variables before beginning therapy. To verify the precise allergens to which the person has antibodies, skin or blood testing are used. Immunotherapy is typically advised only if a person appears to be allergic to many allergens selectively.

Subcutaneous immunotherapy (SCIT), often known as allergy shots, is the most frequent and successful method of allergy immunotherapy. This is the only medication that genuinely alters the immune system, allowing for the prevention of new allergies and asthma attacks. Allergy tablets are a type of sublingual immunotherapy (SLIT) that allows people to treat allergies without having to use shot.

Like shots, tablets also lessen the symptoms by assisting the body in developing tolerance to the effects of an allergen. Tablets, unlike shots, target just one kind of allergen and do not prevent the onset of new allergies or asthma. Allergy drops is a type of SLIT that works similarly to tablets. Drops are widely recognized and used in many countries across the world, but in the United States, they are not FDA authorized and are used off-label. An allergist recommends right treatment to get patients health on track.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing prevalence of asthma and allergic disorders of the respiratory tract because of increasing pollution is projected to boost the market growth during the forecast period.
• Growing development of innovative immunotherapy products by key companies is anticipated to propel the market growth during the forecast period.
• Increased emphasis on research for the development of immunotherapy solutions against food allergens is expected to drive the market growth during the forecast period.
• Increasing side-effects like skin-related disorders, gastrointestinal and respiratory disorders due to treatment is projected to hamper the market growth.
• High cost of treatment which is not affordable by everyone is expected to restrict the market growth during the forecast period.
• Upcoming immunotherapy product launches for the treatment of a variety of food allergies, including milk, peanut, kiwi, and peach allergies is projected to offer lucrative opportunities for the market players.

Scope of Allergy Immunotherapy Market Report

The report on the global allergy immunotherapy market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Allergy Immunotherapy Market Segment Insights

Subcutaneous Immunotherapy segment is expected to account for a key share of the market

Based on treatment type, the allergy immunotherapy market is segmented into subcutaneous immunotherapy, sublingual immunotherapy, tablets, and drops. The subcutaneous immunotherapy (SCIT) segment is expected to account for a key share of the market during the forecast period owing to its increasing adoption in allergy immunotherapy and its efficiency. Allergy rhinitis, asthma, and stinging insect hypersensitivity can all be treated with this therapy. SCIT has also proven to be useful in the treatment of several allergens. As a result, SCIT has a greater adoption rate than SLIT.

On the other hand, the Sublingual Immunotherapy (SLIT) segment is anticipated to expand at a rapid pace during the forecast period due to its increasing adoption as significant alternative for patients who cannot receive allergy shots. Odactra, Grazax, Oralair, and Ragwitek are some of the FDA-approved SLIT tablets now available in the United States. In the future, liquid formulations are likely to be licensed for therapeutic use in the United States. This would boost the SLIT segment's growth in the country.

Allergic rhinitis segment is expected to account for a key share of the market

Based on allergy type, the allergy immunotherapy market is segmented into allergic rhinitis, allergic asthma, and others. The Allergic rhinitis segment is expected to account for a key share of the market during the forecast period due to its increasing prevalence worldwide. According to the American College of Allergy, Asthma & Immunology, asthma affects 24 million individuals in the United States, including 6 million children. The market is likely to benefit from the increased disease burden associated with allergy diseases.

Hospital pharmacy segment is expected to account for a key share of the market

Based on distribution channel, the allergy immunotherapy market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is expected to account for a key share of the market during the forecast period owing to increasing prevalence of patient seeking treatment for allergic disorders. Allergy shots are often given in hospitals or doctors' clinics to track and manage any adverse effects. Belgium's healthcare facilities have recommended establishing a national registry for allergy immunotherapy at hospitals and clinics in order to increase the therapy's adoption. Furthermore, after a few months of therapy, SLIT may be taken at home, and the medications can be purchased through an online channel.

Europe is anticipated to dominate the market

On the basis of regions, the allergy immunotherapy market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to the presence of key players such as ASIT Biotech, Circassia, Mylan N.V., and Merck KGaA. Large number of people in this region are affected by allergic disorders because of conditions such as industrialization, urbanization, climate change, and pollution.

Furthermore, an increase in the number of allergy drop approvals in Europe resulted in a higher share of the market in this region. The introduction of allergy immunotherapy in Europe and North America has shown significant differences as well as similarities. The availability and formulation of allergen extracts, as well as their adoption, differ. In Europe, for example, SLIT accounts for a considerable portion of allergen-specific immunotherapy treatment.

In the United States, however, just a few allergists prescribe the treatment. Nonetheless, both areas place a strong emphasis on research and development in order to develop effective and safer allergen-specific immunotherapy treatments. On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to the presence of major companies in developing Asian countries, as well as investments in SLIT development, dose standardization, and long-term outcomes evaluation.

Segments

The global allergy immunotherapy market has been segmented on the basis of

Treatment Type

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
• Tablets
• Drops

Allergy Type

• Allergic rhinitis
• Allergic asthma
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• ASIT Biotech
• Circassia
• Mylan N.V.
• Adamis Pharmaceuticals Corporation
• Merck KGaA
• Stallergenes Greer plc
• Allergy Therapeutics
• ALK-Abelló A/S
• DESENTUM OY
• HAL Allergy B.V.
• HollisterStier Allergy
• LETIPharma
• DBV Technologies SA

Competitive Landscape

Key players competing in the allergy immunotherapy market are ASIT Biotech; Circassia; Mylan N.V.; Adamis Pharmaceuticals Corporation; Merck KGaA; Stallergenes Greer plc; Allergy Therapeutics; ALK-Abelló A/S; DESENTUM OY; HAL Allergy B.V.; HollisterStier Allergy; LETIPharma; DBV Technologies SA.

To maintain a competitive advantage, industry participants place a greater emphasis on the development of novel products. For example, in October 2019, Stallergenes Greer Ltd. partnered with Anergis, a clinical-stage biopharmaceutical firm located in Switzerland, to launch a research study evaluating second-generation contiguous overlapping peptides allergen immunotherapy for birch pollen allergy.

Other business strategies includes mergers, acquisitions, partnerships, collaborations, and capacity expansion to increase their market shares. In 2019, Mylan N.V. reported production delays, which resulted in a North American shortage of its flagship allergy medicine EpiPens. Adamis Pharmaceuticals took advantage of this opportunity by partnering with Sandoz, a Novartis unit, to distribute SYMJEPI, a competitor to EpiPens. Type 1 allergic responses, such as allergen immunotherapy, anaphylaxis, and other allergic diseases, are treated with SYMJEPI.